Analyzing Oruka Therapeutics (NASDAQ:ORKA) & Celldex Therapeutics (NASDAQ:CLDX)

Oruka Therapeutics (NASDAQ:ORKA) and Celldex Therapeutics (NASDAQ:CLDX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, earnings, institutional ownership, risk and valuation.

Valuation and Earnings

This table compares Oruka Therapeutics and Celldex Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oruka Therapeutics	N/A	N/A	-$5.34 million	($6.26)	-1.67
Celldex Therapeutics	$7.02 million	195.46	-$141.43 million	($2.45)	-8.44

Oruka Therapeutics has higher earnings, but lower revenue than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Oruka Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and price targets for Oruka Therapeutics and Celldex Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oruka Therapeutics	0	0	7	2	3.22
Celldex Therapeutics	0	2	5	1	2.88

Oruka Therapeutics currently has a consensus price target of $39.86, suggesting a potential upside of 281.04%. Celldex Therapeutics has a consensus price target of $55.38, suggesting a potential upside of 167.90%. Given Oruka Therapeutics’ stronger consensus rating and higher probable upside, equities analysts plainly believe Oruka Therapeutics is more favorable than Celldex Therapeutics.

Risk & Volatility

Oruka Therapeutics has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500. Comparatively, Celldex Therapeutics has a beta of 1.76, meaning that its stock price is 76% more volatile than the S&P 500.

Profitability

This table compares Oruka Therapeutics and Celldex Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oruka Therapeutics	N/A	-24.96%	-21.22%
Celldex Therapeutics	-1,544.32%	-19.75%	-18.86%

Insider & Institutional Ownership

56.4% of Oruka Therapeutics shares are owned by institutional investors. 22.7% of Oruka Therapeutics shares are owned by company insiders. Comparatively, 3.8% of Celldex Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Oruka Therapeutics beats Celldex Therapeutics on 9 of the 14 factors compared between the two stocks.

About Oruka Therapeutics

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

About Celldex Therapeutics

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company’s clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.